Carregant...
Adnectin-Based Design of Chimeric Antigen Receptor for T Cell Engineering
Although chimeric antigen receptor (CAR)-engineered T cell therapy has achieved encouraging clinical trial results for treating hematological cancers, further optimization can likely expand this therapeutic success to more patients and other cancer types. Most CAR constructs used in clinical trials...
Guardat en:
| Publicat a: | Mol Ther |
|---|---|
| Autors principals: | , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
American Society of Gene & Cell Therapy
2017
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5675441/ https://ncbi.nlm.nih.gov/pubmed/28784559 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ymthe.2017.07.009 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|